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ABSTRACT
Nucleotides are required for a wide variety of bio-
logical processes and are constantly synthesized de
novo in all cells. When cells proliferate, increased
nucleotide synthesis is necessary for DNA replica-
tion and for RNA production to support protein syn-
thesis at different stages of the cell cycle, during
which these events are regulated at multiple lev-
els. Therefore the synthesis of the precursor nu-
cleotides is also strongly regulated at multiple levels.
Nucleotide synthesis is an energy intensive process
that uses multiple metabolic pathways across differ-
ent cell compartments and several sources of car-
bon and nitrogen. The processes are regulated at the
transcription level by a set of master transcription
factors but also at the enzyme level by allosteric reg-
ulation and feedback inhibition. Here we review the
cellular demands of nucleotide biosynthesis, their
metabolic pathways and mechanisms of regulation
during the cell cycle. The use of stable isotope trac-
ers for delineating the biosynthetic routes of the mul-
tiple intersecting pathways and how these are quan-
titatively controlled under different conditions is also
highlighted. Moreover, the importance of nucleotide
synthesis for cell viability is discussed and how this
may lead to potential new approaches to drug devel-
opment in diseases such as cancer.
INTRODUCTION
A large fraction of the genome is now known to be tran-
scribed into a wide range of RNAs whose functions are still
being ascertained (1–4). Even in quiescent cells, there is con-
siderable turnover of RNA involved in cell maintenance,
repair and regulation. Proliferating cells must up-regulate
RNA and DNA biosynthesis as an essential component of
cell division, which can modulate, at least in part, the rate
of the overall cell cycle (5,6). This requires increased expres-
sion of the genes associated with nucleotide synthesis in late
G1 phase (5–15).
Nucleotide synthesis is regulated by several critical tran-
scription factors (cf. Table 1), MYC and Rb/E2F in par-
ticular, which if mutated or overexpressed are associated
with transformation and uncontrolled proliferation leading
to cancer (16–23). MYC directly regulates the expression
of genes that encode the enzymes in the nucleotide biosyn-
thetic pathways and in the feeder pathways for the produc-
tion of the precursors of all nucleotides (15,24–26), as well
as coordinatesRNAand protein biosynthesis (27,28).MYC
also influences expression of specific microRNAs that reg-
ulate enzymes required for cell proliferation (22,29–31).
Despite its functional importance, nucleotidemetabolism
and cell cycle control have received much less attention
than genomics and functional genomics, although there
have been multiple metabolic targets derived from the rel-
evant processes for human disease therapy, such as the an-
timetabolites MTX (32,33), gemcitabine (34), purine ana-
logues (35), suicide inhibitors like 5-FU (36), a range of an-
tiviral nucleotide analogues (37,38) and traditional RNA-
seeking antibiotics (39).
Although numerous recent reviews have dealt with
metabolic adaptations in proliferating cells (40–50), there
has been little emphasis on nucleotide biosynthesis and its
regulation. Here we review the regulation of energy and
metabolic pathways needed for nucleotide biosynthesis in
proliferating mammalian cells.
CELLULAR CONTENT OF NUCLEOTIDES AND NU-
CLEIC ACIDS
RNA and DNA content of mammalian cells
The DNA content of cells in an organism is fixed, and does
not depend on the cell size. In contrast, other cellular com-
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Table 1. Genes and enzymes involved in nucleotide biosynthesis
Gene name Enzyme Chromosome location Reaction (Figure No.) Predicted and known regulators
1. Purines
PRPS Phosphoribosyl Pyrophosphate
Synthetase
Xq22.3 (Supplementary Figure S1) GR Sox5 p53 FOXD1 Nkx2-5 FOXO3b
POU2F1 POU2F1a FOXO4 GR-alpha
PPAT phosphoribosyl pyrophosphate
amidotransferase
4q12 1 (3) Bach1, GATA-1, Bach2, C/EBPa,
CHOP-10, Brachyury,Roaz, Arnt,
USF-1; MYC
GART Trifunctional enzyme.
Phosphoribosylglycinamide
Formyltransferase
Phosphoribosylglycinamide
Formyltransferase,
Phosphoribosylglycinamide
Synthetase;
Phosphoribosylaminoimidazole
Synthetase
21q22.11 2,3,5 (3) SRY, HOXA9, HOXA9B, Meis-1,
CUTL1, Stat5a, FOX O3/O3a/ O3b,
MYC
PFAS Formylglycinamide ribotide
amidotransferase
17p13.1 4 (3) AML1a,MAX,MAX1;MYC
PAICS Bifunctional Phosphoribosyl
aminoimidazole Carboxylase
4q12 6,7 (3) AREB6, p53, CP2, STAT3, MyoD,
MYC
ADSL Adenylosuccinate Lyase 22q13.2 8 (3) MEF-2,RORa2,
12 (S2) ARP-1,POU2F 1,1a,F2,F2B; MYC
ATIC Bifunctional
5-Aminoimidazole-4-Carboxamide
Ribonucleotide
Formyltransferase/IMP
Cyclohydrolase
2q35 9,10 (3) FOXO1/a, C/EBPb,SREBP-1a,b,c,
NFkB, AP-1, c-jun; MYC
IMPDH1 IMP dehydrogenase 7q31.3-q32 13 (3) c-Fos USF1 AP-1 NRF-2 USF-1 c-Jun
MYC
GMPS GMP synthetase 3q25.31 13 (3) E2F-4 E2F-3a E2F-5 E2F-1 E2F p53
E2F-2 C/EBPalpha
ADSS Adenylosuccinate synthetase 1q44 11 (3) USF1 Pax-5 NRSF form 1 USF2
CUTL1 NRSF form 2 Roaz FOXC1
STAT3 IRF-7A
ADSL Adenylosuccinate Lyase 22q13.2 12 (S2)
8 (3)
AK1 Adenylate kinase 9q34.1 c-Fos p53 AP-2alpha isoform 3 AP-1
AP-2alpha isoform 2 AP-2alpha isoform
4 c-Jun AP-2alpha AP-2alphaA
NME Nucleoside Diphosphate Kinase 17q21.3 c-Fos AP-1 ATF-2 c-Jun
2. Pyrimidines
CAD, trifunctional Carbamoyl-Phosphate Synthetase 2 2p22-p21 1 (Figure 2) PPAR-gamma1 AP-1 ATF-2 MyoD
c-Jun PPAR-gamma2 CUTL1 ;MYC,
Hif1a, ER, SP-1
Aspartate Transcarbamylase 2 (Figure 2)
Dihydroorotase 3 (Figure 2)
DHODH Dihydroorotate Dehydrogenase 16q22 4 (Figure 2) AhR AML1a p300 CUTL1 NF-kappaB
POU3F2 Evi-1 Arnt GATA-2
NF-kappaB1 ; MYC
UMPS Bifunctional Uridine
Monophosphate Synthetase:
orotate phosphoribosyltransferase
3q13 5 (Figure 2) POU2F1a ER-alpha AML1a HTF
AREB6 E2F E2F-1 POU2F1 POU2F1a
; MYC
UMPS OMP decarboxylase 3q21.2 6 (Figure 2) ER-alpha AML1a HTF AREB6 E2F
E2F-1 POU2F1 POU2F1a
NME Nucleoside Diphosphate Kinase 17q21.3 c-Fos AP-1 ATF-2 c-Jun ; MYC
CTPS CTP Synthase 1,2 1p34.1
3. ribose/PPP
G6PD Glucose-6-phosphate
dehydrogenase
Xq28 (Figure 1) TBP p53 ATF-2 c-Jun
H6PD D-glucono-1,5-lactone lactone
hydrolase (also G6PDH activity)
1p36 (Figure 1) ER-alpha Spz1 NF-1 GCNF
RORalpha2 Max GCNF-1 Ik-1 c-Myc
PGD 6-phosphogluconate dehydrogenase
(deficiency not associated8 (3) with
disease)
1p36.22 (Figure 1) Bach1 Sox5 NF-1/L NF-1 HOXA5
NF-AT C/EBPalpha
RPIA ribose 5-phosphate isomerase A 2p11.2 (Figure 1) NMyc GR AML1a NCX/Ncx MyoD
GR-alpha LCR-F1
RPE ribulose 5-phosphate epimerase 2q32-q33.3 (Figure 1) Sp1 AP-1 ATF-2
TALDO1 Transaldolase 1 11p15.5-p15.4 (Figure 1) Pax-5 POU3F1 CUTL1 HNF-3beta
YY1 AREB6 SRY FOXO4 FOXJ2
TKT transketolase 3p14.3 (Figure 1) NF-1 Sp1 p53 HFH-1 LUN-1 Egr-4
C/EBPalpha
4. Feeder pathways
GOT1 Glutamic-Oxaloacetic
Transaminase8 (3) (cytoplasmic)
10q24.1-q25.1 STAT1 STAT1beta Egr-4 STAT1alpha
AREB6 Egr-2 PPAR-gamma1 FOXO1a
PPAR-gamma2 FOXO1
GOT2 Glutamic-Oxaloacetic
Transaminase (mitochondrial)
16q21 MIF-1 NF-kappaB GATA-2 AREB6
SRY POU2F1a NF-kappaB2 FOXJ2
(long isoform) FOXJ2 NF-kappaB1
GLUD1 Glutamate dehydrogenase 1 10q23.3 HOXA9B HOXA9 ER-alpha Elk-1
Pax-2 Pax-2a FOXJ2 (long isoform)
ZIC2/Zic2 Meis-1a Meis-1
PHGDH 3-Phosphoglycerate Dehydrogenase 1p12 2 (Figure 4) GRMax1 IRF-1 CUTL1 PPAR-alpha
Max NRF-2 GR-alpha c-Myc
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Table 1. Continued
Gene name Enzyme Chromosome location Reaction (Figure No.) Predicted and known regulators
PSAT1 Phosphoserine Aminotransferase 1 9q21.2 3 (Figure 4) POU2F2 (Oct-2.1) Oct-B1 oct-B3
oct-B2 POU2F2 POU2F2C POU2F1
POU2F1a c-Jun POU2F2B
PSPH Phosphoserine Phosphatase 7p11.2 4 (Figure 4) AREB6 GR CREB p53 deltaCREB
SEF-1 (1) GR-alpha Nkx2-5
SHMT1 Serine Hydroxymethyltransferase 1
(cyto)
17p11.2 5 (Figure 4) AhR CHOP-10 CBF-B CBF-A NF-YA
c-Myb CP1A NF-Y CBF(2)
C/EBPalpha
SHMT2 Serine Hydroxymethyltransferase 2
(mito)
12q12-q14 5 (Figure 4) E2F-3a E2F-1 Sp1 E2F-2 GATA-1
TYMS Thymidylate synthetase 18p11.32 AML1a p53 ATF-2 Egr-1 RREB-1
FAC1 POU2F1 POU2F1a ARP-1
MRF-2 MYC
DHFR Dihydrofolate reductase 5q11.2-13.2 USF1 Sp1 p53 USF-1:USF-2
C/EBPalpha Pax-3 POU2F1 POU2F1a
USF-1
MTHFD1 Trifunctional:
Methylenetetrahydrofolate
Dehydrogenase (NADP+
Dependent) 1,
Methenyltetrahydrofolate
Cyclohydrolase,
Formyltetrahydrofolate Synthetase
14q24 RFX1 NF-YA NF-YC STAT5A CBF-C
NF-YB HOXA5 CP1A CP1C NF-Y
RRM1 Ribonucleotide reductase subunit 1 11p15.5 E2F-4 E2F-3a E2F-5 E2F E2F-1 p53
HOXA5 Lmo2 E2F-2 ; MYC
RRM2 Ribonucleotide reductase subunit 2 2p25-p24 CREB AP-2alpha isoform 3 Sp1 AP-1
deltaCREB AP-2alpha isoform 4
AP-2alpha isoform 2 AP-2alpha
AP-2alphaA
The gene nomenclature and regulation (including allosteric regulators) refer to mammalian systems. Predicted transcription factors are from http://www.genecards.org/, which recognize consensus binding
sites in the promoters of given genes. Factors in bold represent those experimentally verified by at least one method.MYC binding to gene promoters is mainly from Liu (15); MYC regulation of TS, IMPDH2,
PRPS2 is from (24) and E2F from (17). MYC regulation of nucleotide biosynthesis was confirmed by Kim et al. (28).
ponents depend on cell volume, as the concentration is regu-
lated. Thus, the protein concentration ofmammalian cells is
about 200 mg/ml (20% solution), which can occupy ∼16%
of the cell volume, not counting the shells of ‘bound’ water
in macromolecules. However, cell volumes vary widely - by
more than an order of magnitude even for a given organism
(see below). This means that the macromolecular content
per cell with the exception of DNA varies over a factor of
10-fold or more from one cell type to another.
Quiescent mammalian cells in G0 or G1 are typically
diploid, and contain the minimum amount of both DNA
and RNA. In order to pass into S phase, the genes for DNA
biosynthesis must first be upregulated. Furthermore, ac-
tively proliferating cells must double other macromolecular
content as they enter M phase and divide into two daugh-
ter cells. As the major macromolecular component of cells
is protein, protein biosynthesis must also be greatly upreg-
ulated during S phase. This will require an increase in the
number of ribosomes and thus rRNA, as well as the con-
comitant energy production needed to meet the enhanced
demand for the highly endergonic nucleotide biosynthe-
sis (7,13,51). However, it has been argued that the utiliza-
tion for macromolecule biosynthesis is a small fraction of
the total cellular adenosine triphosphate (ATP) consump-
tion (52,53). Nevertheless, the ATP concentrations (and
probably the more relevant ATP/ADP.Pi ratio which is the
thermodynamic potential (54,55)) cannot fall below criti-
cal levels to maintain cell viability. The ATP requirements
show a hierarchy of proliferation > maintenance and re-
pair > membrane potential (46,56–57), i.e. proliferation
ceases first, while maintaining membrane potentials goes
last. However in mouse Ehrlich Ascites cells, no such en-
ergy hierarchy was detected (58).
The content of mammalian cell biomass has been doc-
umented for different conditions (59,60). However, it is im-
portant to specify the cell type and conditions, whether it be
cells in G0/G1 or proliferating cells, as well as the cell size.
For example, all proliferating cells double their biomass as
they complete a cell cycle. However, in the diploid state, the
amount of DNA per cell is independent of the cell size, as
it is fixed by the genome C-value (61). For human diploid
cells, this is about 6.5 pg per cell based on 6 billion base
pairs. However, cell volumes vary greatly, at least by an or-
der of magnitude from small hematopoietic cells of 0.2–0.5
pl to large hepatocytes of volume>5 pl (60,62–63). As other
macromolecules are maintained at about the same concen-
tration per cell, the biomass content scales with cell size, as
has been emphasized recently by Vaquez et al. (51).
Biomass accounts for around 30% of the cell volume
(i.e. 70% water v/v). Given the relative abundances of the
various macromolecules, their effective partial specific vol-
umes and the density of mammalian cells, (64–66), (67) the
biomass content of a cell is ca. 0.35–0.4 g/ml. In resting
cells, biomass comprises ∼50–60% protein, 15% lipid, 5%
carbohydrates, 5% small metabolites and ions, and the re-
mainder the nucleic acids (i.e. ca. 15–20%). In a small cell,
the DNA content may be up to 3% of the biomass, but
in a large cell it is a much smaller fraction (cf. 0.2%). The
remaining nucleic acid content is RNA, of which 85% is
rRNAand<5% ismRNA.Mammalian cells have been said
to have an RNA content of 3% of the biomass (68). How-
ever, this seems to be rather variable depending on cell type
and size (58). Note that this is considerably less than the
>20% estimated for Escherichia coli (52).
The RNA content of a cell does not necessarily represent
the amount of RNA synthesis however, because the RNAs
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are synthesized as larger precursors that are then processed
to the mature size, with recycling of the released mononu-
cleotides. For example the ratio of intron to exon length in
the human genome is about 28 (69) and the length of ma-
ture rRNAs are about 50% of the pre rRNA transcript (70).
This requires at least three-fold more RNA synthesis than
the amount of mature RNA present in the cell.
Increased protein biosynthetic rate scales with cell size
and progression into S-phase. To make protein faster, the
cell mustmakemore ribosomes, which requires more rRNA
and therefore an increase in the rate of production of
rNTPs, which suggests that RNA and protein biosynthe-
sis are coordinately regulated. It has been shown that
MYC and its downstream target translation initiation fac-
tor eIF4E achieve this via controlling the cis-regulatory ele-
ment in the 5′ UTR of phosphoribosylpyrophosphate syn-
thetase (PRPS2) (27), which catalyzes the first committed
step in nucleotide biosynthesis (cf. Figures 1 and 3A).
Cellular concentrations of rNTPs and ATP requirement for
nucleic acid metabolism
To sustain energy and precursors for RNA biosynthesis, the
ATP concentration in cells is generally maintained above 1
mM (71) with a high ATP/ADP.Pi ratio (72), so that there
is sufficient free energy available to drive endergonic reac-
tions. There are limits to the maintenance of these levels,
below which different aspects of the cell functions cease,
eventually leading to necrotic cell death (57,73–74). Some
cells maintain very high concentrations of ATP (>5 mM)
for specialized mechanical work, such as skeletal muscle
(75) and cardiac myocytes (76). Similarly, other rNTPs are
maintained at sufficient concentrations to activate and drive
anabolic processes (see above) while supplying the materi-
als for nucleic acid synthesis. Thus in cells, it is typically
observed that the nucleotide concentrations are in the or-
der ATP > UTP > GTP > CTP with the CTP level kept
at ∼1 mol/g (77,78). Nucleotide sugars are also needed
to activate metabolites for various anabolic processes in-
cluding UDP-glucose and other UDP-hexoses (for car-
bohydrates synthesis), CDP-choline (for lipid synthesis),
GDP sugars (e.g. GDP mannose for glycosyltransferases),
NAD(P)+,FAD/FMN (for mediating redox reactions) and
ADP ribosylation for a wide range of regulatory func-
tions (79,80). Collectively these compounds are typically
present at >1 mM. For a cell of 1 pl volume, the amount
of nucleotides is of the order 4–10 fmol. To maintain these
pools at constant concentrations as a cell divides, these nu-
cleotides must be synthesized.
For a cell to divide, the entire biomass including metabo-
lites (which is cell size dependent) is doubled as it pro-
gresses from the beginning of G1 through the cell cycle
and cytokinesis. As described above, a cell with a volume
of 0.2–5 pl has a biomass content of 0.08–2 ng, compris-
ing roughly 0.05–1.2 ng protein, 0.01–0.3 ng RNA, 6.5 pg
DNA, 0.01–0.3 ng lipid and 0.004–0.1 ng each of carbo-
hydrates and metabolites. The nucleic acids for cell dou-
bling alone amount to 50–950 fmol nucleotides, which use
eight ATP equivalents on average for de novo synthesis or
0.4–8 pmol ATP. However, as the RNAs are synthesized as
larger precursor molecules and energy is required for recy-
cling the released nucleoside monophosphate (NMPs), the
actual ATP usage for RNA synthesis must be larger. For
nucleic acid biosynthesis, which is energetically costly, the
nucleotide synthesis consumes 0.5–9 pmol exogenous car-
bon, which is comparable in number to the ATP hydrolysis.
Thus, to make nucleic acids for cell proliferation purposes,
cells have to upregulate both energy metabolism and the
nucleotide biosynthetic pathways. As expected nucleotide
biosynthesis is greatly stimulated as cells enter rapid growth
(7,11,16,81). Progression through the cell cycle is tightly reg-
ulated by numerous transcription factors, and is associated
with changes in volume, energy and anabolic metabolism as
cells progress through S-phase (15–16,49,51,62,81–87).
NUCLEIC ACID SYNTHESIS: ENERGETICS AND NU-
TRIENT REQUIREMENTS
To maintain homeostasis, dividing cells need to replenish
nucleotides at the same rate as cell division. Thus, the pro-
gression of the cell cycle must be tightly linked to the ability
of the cell to acquire nutrients, generate metabolic energy
and to drive anabolism, including nucleotide/nucleic acid
biosynthesis. Although there are salvage pathways and cells
can take up nucleotides (88–90), most proliferating cells
synthesize nucleotides and nucleic acids de novo, mainly
from glucose, glutamine and CO2. The metabolic demands
of nucleic acid synthesis have been reviewed recently (47).
Bioenergetics of nucleotide biosynthesis
The different parts of the nucleotides derive from various
carbon and nitrogen sources in the cell (cf. Figures 1–3
and below), and the assembly of the mature rNTPs has a
high metabolic demand. Supplementary Table S1 summa-
rizes the numbers of nucleoside triphosphate (NTP) equiv-
alents (number of phosphates released fromATP andGTP)
needed to make one molecule each of the four rNTPs, ac-
cording to Figures 1–3. Thus starting from glucose, three
ATP equivalents are needed tomake the activated ribose-5′-
phosphoribosepyrophosphate (PRPP), which is produced
by the reaction of 5′-phosphoribose with ATP, driven by
the release of the good leaving group 5′-AMP (Supplemen-
tary Figure S1). The pyrimidine rings are synthesized first as
uracil from aspartate, CO2 (or bicarbonate) and glutamine
(Figure 2), which requires two ATP. One of the biosyn-
thetic steps, i.e. orotate dehydrogenase reaction, occurs in
the mitochondria (91), while the remainder reside in the cy-
toplasm. The amination of U to C consumes an additional
ATP; de novo synthesis of 5′-UMP and 5′-CMP therefore
require four and five molecules of ATP respectively. Aspar-
tate provides three of the four carbon atoms of pyrimidines,
which derive largely from glutamine and to a lesser extent
from glucose (92) (and see below).
Unlike pyrimidines, the synthesis of purine nucleotides
is entirely cytoplasmic, with the nucleobase being built di-
rectly on the activated PRPP (again, using three ATPs start-
ing from glucose) (Figure 3A). The five carbon atoms of the
purine ring derive from CO2, glycine and the one-carbon
unitN10-formyl-TetraHydroFolate (THF), which is derived
from the serine-glycine pathway via N5,N10-methylene-
THF (Figure 4). The sources of serine and glycine may
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Figure 1. Denovo nucleotide biosynthesis: generation of activated ribose. 5-phosphoribose-1-pyrophosphate (PRPP) is the activated form of ribose used for
nucleotide biosynthesis and is derived from ribose-5-phosphate from the pentose phosphate pathway (PPP).Ribose-5-phosphate is produced via both ox-
idative and non-oxidative branches of the PPP. The oxidative branch also generates twoNADPH. The oxidative branch comprises the reactions catalyzed by
G6PD, PGLS and PGD. The non-oxidative branch interconverts five carbon sugars with four and six carbon sugars using the transaldolase (TA) and trans-
ketolase (TK) reactions. HK: hexokinase; G6PD: glucose-6-phosphate dehydrogenase; PGLS: 6-phosphogluconolactonase; PGD: 6-phosphogluconate
dehydrogenase; RPI: ribulose-5-phosphate isomerase; RPE: PGLS 3-epimerase; TK: transketolase; TA: transaldolase.
be exogenous, and/or via de novo synthesis from predom-
inantly glucose (93–96). The production of the common in-
termediate in purine biosynthesis, Inosine Monophosphate
(IMP), uses seven ATPs (Figure 3A; Supplementary Table
S1). An additional GTP or ATP is used to convert IMP
into AMP or GMP, respectively (Figure 3B). The NMPs
are then converted to the triphosphate nucleotides by the
action of nucleotide kinases, which use two additional ATP
molecules for a total of 10. Hence for a genome of 50% GC
content and 6 × 109 nucleotides, DNA replication alone
would consume around 6 × 1010 ATPs per cycle or close to
0.1 pmol ATP/cell and around 15 fmol glucose equivalents
in terms of carbon. The energy demand for RNA synthesis
may be 10-fold higher during a cell cycle, thus accounting
for about 1 pmol ATP/cell.
The production of DNA further requires the reduction
of rNDPs to dNDPs via ribonucletide reductase, which is
NADPH-dependent (97), therefore requiring the supply of
around 0.1 pmol NADPH/cell per division (and see below).
The source of this NADPH is variable according to cell
type (98), but the oxidative branch of the pentose phosphate
pathway (PPP) is an efficient cytoplasmic source, which also
links glucose metabolism to ribose production. As in gen-
eral the DNA content of cells is lower than that of RNA,
and compared with rNTPs, dNTPs have fewer functions
other than nucleic acid synthesis, the concentrations of the
dNTPs relatively low in cells, typically in the micromolar
range in cells in G1, and rising ca. 5–10-fold in late G1 or
during S phase (99,100).
In addition to NADPH, as alluded to earlier, the nu-
cleotide biosynthesis pathways have feeder pathways that
provide for the carbon and nitrogen precursors, including
the amino acids aspartate, glutamine, serine and glycine as
well as CO2. These feeder pathways are glycolysis, the PPP
(Figure 1), the serine-glycine pathways (Figure 4), theKrebs
cycle without or with anaplerotic inputs (Figure 5) and glu-
tamine amidotransferase reactions (Figures 2 and 3).
The metabolic energy needed to drive nucleotide biosyn-
thesis is therefore substantial, and is expected to be de-
rived from a combination of glycolysis and oxidative phos-
phorylation. The ATP yields for oxidation of different sub-
strates assuming perfectly coupled mitochondria are given
in Supplementary Table S2. Different cell types use differ-
ent strategies that are also dependent on the tissue environ-
ment including the nutrient supply, which is a point of fo-
cus for understanding metabolic reprogramming in cancers
(25,44,47,101–107). Although the oxygen concentration in
tissues (e.g. solid tumors) can become quite low, reaching
<1% or 10 M (108,109), it is still sufficient to saturate cy-
tochrome c oxidase, which has a low M Km for oxygen
(110,111). However, othermetabolic reprogramming occurs
at oxygen levels lower than about 2–4%, due to the acti-
vation of HIF1 (112,113), which leads to accelerated gly-
colysis but inhibition of the Krebs cycle activity. HIF1 is
constitutively degraded by the proteasome under normoxia
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Figure 2. Pyrimidine biosynthesis. CA: carbamoyl aspartate; DHO: dihydroorotate; OMP: orotate monophosphate. Enzyme names: (1) carbamoyl phos-
phate synthase II (CPSII); (2) aspartate transcarbamoylase (ATCase); (3) carbamoyl aspartate dehydratase = dihydroorotase [CAD encodes enzymes 1 +
2 + 3]; (4) dihydroorotate dehydrogenase; (5) orotate phosphoribosyltransferase; (6) orotidine-5-phosphate decarboxylase (OMP decarboxylase). The ac-
tivities of 5 and 6 reside in a single bifunctional polypeptide encoded by theUMPS gene. Atom colors denotes origins: red from CO2, green from aspartate
and ultimately glucose or Gln, blue from Gln.
(21% oxygen, ca. 210 M in air-saturated water at 37◦C)
due to the regulation by HIF proline hydroxylase. However,
when oxygen levels drop to below 2–4%, this enzyme activ-
ity is greatly attenuated (114), leading to HIF1 activation
(112,115–116).
Moreover, the cellular respiration rate depends on cell
type, the number of mitochondria present, the nutrient be-
ing oxidized (cf. Supplementary Table S2) and the overall
metabolic demand. The oxygen consumption rate of some
cancer cells has been measured as 4 fmol/min/cell under
normoxia (21% oxygen), to 2 fmol/min/cell under hypoxia
(1% O2) (117–120). Such cells can thus generate ca. 5 fmol
ATP/min under 1% oxygen by oxidative phosphorylation.
When compared with the nucleotide synthesis requirement
during a cell cycle of ca. 1 pmol ATP, it would need about
3 h to produce this amount of ATP from oxidative phos-
phorylation to support nucleotide synthesis alone. How-
ever, hypoxic cells also ferment glucose to lactate, produc-
ing 2 ATP/mol glucose and in cancer cells glycolysis is typ-
ically accelerated many fold (42,121–122), which may pro-
duce ATP at a rate comparable to the more efficient mito-
chondrial oxidation of fuels including fatty acids (104,123),
Gln (25,44–45,81,106,119,124–127) and ketone bodies (46)
(Supplementary Table S2). It is notable that in the intersti-
tial fluid of solid tumors, the glucose levels are very lowwith
depletion of lipids compared with the blood supply in the
tumor (128). This could reflect the high energy demand of
tumor cells, which oxidize nutrients at a high rate.
Enzymes and gene locations involved in nucleotide biosynthe-
sis and ‘feeder’ pathways
Figures 1–4 and Table 1 lists the enzymes and genes directly
involved in the de novo biosynthesis of nucleotides as well as
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Figure 3. Purine biosynthesis: synthesis of IMP. Various atoms of the purine ring originate from different sources, i.e. N3, N9 derive from the amido
group of Gln (blue), N7, C5, C4 derive from Gly (green), C6 from CO2 (black), N1 from the amino group of Asp (red) and C2, C8 from N10formyl-
tetrahydrofolate. Enzyme names: (1) glutamine phosphoribosylpyrophosphate amidotransferase (PPAT); (2) glycinamide ribotide synthase (GART); (3)
glycinamide ribotide transformylase (GART); (4) formylglycinamide synthase (PFAS); (5) aminoimidazole ribotide synthase (GART); (6) aminoimidazole
ribotide carboxylase (PAICS); (7) succinylaminoimidazolecarboxamide ribotide synthase (PAICS); (8) adenylosuccinate lyase (ADSL); (9) aminoimidazole
carboxamide ribotide transformylase (ATIC); (10) IMP cyclohydrolase (ATIC). IMP is the common precursor of AMP and GMP. The pathway from IMP
to GMP and AMP are shown in Supplementary Figure S2.
Figure 4. Glycine, serine and aspartate pathways. Synthesis of glycine and N5,N10-methylene tetrahydrofolate (N5,N10-CH2-THF) from glucose via the
One-Carbon pathway. N5,N10-CH2-THF is further converted to N10-formyl-THF for incorporation into purine rings. Enzymes: 1: Hexokinase (HK);
2: 3-phosphoglycerate dehydrogenase (PHGDH); 3: phosphoserine aminotransferase (PSAT); 4: phosphoserine phosphatase (PSPH); 5: Serine Hydrox-
ymethyltransferase (SHMT).
the relevant ‘feeder pathways’ that supply the carbon, nitro-
gen and phosphorus, as well as metabolic energy. The genes
are distributed over nine chromosomes for the purines and
five for the pyrimidines, plus several others for the ‘feeder
pathways’. The expression of the genes is thought to be
controlled by several transcription factors, though relatively
few have been directly demonstrated experimentally.
A notable feature of the enzymes involved in nucle-
obase biosynthesis is the multifunctional nature, including
PPAT, GART and MTHFD1 for purines and carbamoyl
phosphate synthase II (CPSII) aspartate transcarbamoylase
(ATCase) dihydroorotase trifunctional enzyme (CAD) and
UMPS for pyrimidines. These enzymes are thought to be
rate limiting in nucleotide biosynthesis, though in practice
this concept may not be helpful in understanding regulation
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Figure 5. Atom resolved tracing from glucose and glutamine into ribonucleotides. The 13C labels from 13C6-Glc ( ) are incorporated into the ribose unit
(via PPP), uracil ring (via the Krebs cycle–pyrimidine synthesis path or PYR) of UMP or adenine ring (via the one-carbon or 1-C to purine synthesis
path or PUR) of AMP (structures shown). The 13C ( ) and 15N labels ( ) from 13C5,15N2-Gln are expected to go into the uracil ring (via the anaplerotic
glutaminolysis or GLS-Krebs cycle-PYR path) of UMP and the adenine ring (via the PUR path) of AMP. The color of the label for atomic positions in
the UMP and AMP structures is matched with that of 13C or 15N label derived from the glucose or glutamine tracer, except for C4-C6 of UMP where
glucose or Gln-derived 13C is not delineated. Three examples of labeled uracil ring delineate contribution of 13C from 13C6-Glc or 13C5,15N2-Gln after
one Krebs cycle turn without or with pyruvate carboxylation. The 13C labeling patterns of the Krebs cycle intermediates and Asp account for the 13C
scrambling in succinate due to its symmetry and anaplerotic input (green arrows and ) from pyruvate carboxylation into the Krebs cycle after the first
turn. Open circles: 12C; HK: hexokinase; G6PDH: glucose-6-phosphate dehydrogenase; PDH: pyruvate dehydrogenase; GLS: glutaminase; PCB: pyruvate
carboxylase; OAA: oxaloacetate; KG: -ketoglutarate; exo: exocyclic.
(129–132). This is because a coordinate activation of mul-
tiple enzymes is necessary for enhancing flux through the
pathway (131,133).
Coordinate regulation of expression and flux control
The rate of cell growth is ultimately limited by the supply
of materials and energy, and therefore by the flux through
the relevant metabolic pathways. Nucleic acid biosynthe-
sis, like any other complex intersecting metabolic networks
requires coordination. The flux through even a simple lin-
ear pathway depends on the supply of the initial metabo-
lite, the concentration and activities of all of the enzymes
in the pathway, and the presence of any feedback or other
regulatory controls. It is not well appreciated that the con-
trol of flux generally does not reside in any single enzyme or
even the same enzymes under all conditions (129,131–134).
Fundamentally, at steady state, the flux is the same at every
point in the pathway. The concept of a rate-limiting enzyme
is therefore at best conditional. In metabolic control analy-
sis (MCA), the goal is to decipher how much control each
enzyme in a pathway exerts on the net flux (which can be
non-zero only where the system is not at equilibrium). A
rate-limiting step in a multistep process is one that controls
the net flux, such that changes in any of the other steps in the
process have no influence on the rate. Glycolysis for exam-
ple, is often considered to have three rate-limiting enzymes,
HK, PFK-1 and PK. A single rate limiting enzyme is one
that completely controls the pathways flux and its flux con-
trol coefficient (FCC) is unity. FCC is defined as ∂lnJ/∂lnvi
where J is the net flux and vi is the enzymatic activity of
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the ith enzyme. If there are three equally rate limiting steps,
then the flux control is shared equally among the three en-
zymes. As the sum of the FCC is unity, then each enzyme
now has an FCC of one-third (131). In the context ofMCA,
this is equivalent to having the FCC of 0.33 for each of these
enzymes, which is a form of distributed flux control. This
means that changing the concentration of any one of these
enzymes by 10-fold will change the flux by only a factor of
2, compared with a 10-fold change in flux if these enzymes
were simultaneously changed 10-fold. In poorly vascular-
ized tumors, however, the flux control resides mainly at the
glucose uptake and HK steps (46,135).
Distributed control is a general feature ofmetabolic path-
ways. Even if there is one enzyme that is rate limiting, in-
creasing its activity indefinitely will only transfer the rate
limiting step to other enzymes in the pathway, thereby lim-
iting the effect of up regulating a given enzyme activity (by
expression or other enzyme-level activity control).
In pyrimidine biosynthesis, the rate limiting step has been
described as CPSII (the first enzyme of CAD) (11) and di-
hydroorotate dehydrogenase (DHODH) (136), the fourth
step in the pathway (Figure 2), again implying distributed
flux control. This and the fact that several enzymes in both
purine and pyrimidine biosynthesis have activities residing
on a single polypeptide chain indicates a level of coordinate,
stoichiometric expression and the possibility of channeling
intermediates from one enzyme to another (see next sec-
tion).
A means to coordinate expression of functionally linked
enzymes that are coded for on different chromosomes is to
make use of a common or a set of transcription factors. Al-
though the promoters of the nucleotide genes have binding
sites for a variety of transcription factors, there are many
in common, one that stands out is MYC (along with related
factors that interact withMYC (e.g. MAX and E2F), which
have been independently verified by validation experiments
such as MYC promoter occupancy assays (Table 1). The
regulation of the expression of many genes by MYC is also
linked to signaling pathways that respond to growth sensing
cues, such as the EGFR/MAP kinase pathway (5,137–139),
Hif1/2 (140–142) or estrogen receptor/Sp1 (137,143) for
CAD regulation. Although not yet completely understood,
cross-talk among these gene regulatory networks is likely to
add additional complexities to homeostatic control.
In addition to transcriptional-level regulation, direct
modulation of various enzyme activities of the pathways is
important, as described below.
Substrate level control
Several of the enzymes involved in nucleotide biosynthe-
sis are regulated at the enzyme level by allosteric interac-
tions, primarily by feedback inhibition. For example, the
activities of the enzymes PPAT and CAD multifunctional
enzymes are strongly inhibited by relevant pathway prod-
ucts (11,139). Purine biosynthesis is inhibited by AMP and
GMP and Pi that act on PRPP synthetase (Supplementary
Figure S1) (7) and byAXPandGXP (adenosine and guano-
sinemono, di or trihosphates) at two sites on the PRPP ami-
dotransferase (Figure 3) (144–146). It is also evident that
PRPP amidotransferase activity may be stimulated by the
substrate PRPP (147). The branch point at IMP to AMP
and GMP (Supplementary Figure S2) is further regulated
by allosteric interactions, in which AMP and GMP inhibit
the adenylosuccinate synthetase and IMP dehydrogenases,
respectively (148–150). The enzyme activities therefore de-
pend not only on the concentrations of the immediate sub-
strates, but also on the end products. Substrate availability
in eukaryotic cells can be an importantmeans of controlling
flux through pathways, either by physical compartmenta-
tion (important in pyrimidine biosynthesis) or by diffusion
limits between different pools in large cells (151).
A potentially powerful means of overcome
kinetic/diffusion limitations is to channel intermedi-
ates in multienzyme complexes (152,153). The observation
that several of the enzymes in mammals are expressed
as multifunctional enzymes (Figures 2 and 3, Table 1),
and that these activities do not always catalyze sequential
reactions has lead to the hypothesis that there might be
a purinosome (91), in which intermediates are channeled
rather than freely equilibrating with the bulk cytoplasm.
Whereas the evidence for specific stoichiometric asso-
ciations in vivo is weak, kinetic experiments in vitro are
consistent with channeling, implying the possibility of
weak and transient complex formation (154). Putative
purinosome bodies have been detected in vivo (91), but they
may also be artifacts of the constructs used for visualization
(155).
The pyrimidine synthesis pathway is controlled by feed-
back inhibition by UTP acting on the CPSII domain of the
CAD trifunctional enzyme (Figure 2, Table 1) (5,11), which
is also activated by PRPP, thereby integrating regulation
of purine and pyrimidine biosynthesis (11). As for purine
biosynthesis, mammalian pyrimidine biosynthesis is char-
acterized by multifunctional enzymes (Table 1), in contrast
to the homologues of E. coli, where CPS and ATCase are
two non-associated polypeptides and are differentially reg-
ulated at the metabolite level (11). For efficient capturing of
the CAD product dihydroorotate (DHO) by the mitochon-
drial DHODH, and the observation of the association of
both CAD and mitochondria with the cytoskeleton, it has
been suggested that CAD could be translocated via the cy-
toskeleton to the DHODH site (11). One complication is
that up to 30% of the CAD may translocate to the nucleus
during the S phase of the cell cycle, when demand for pyrim-
idine biosynthesis is maximal. This would compromise the
DHODH efficiency and favor an alternative moonlighting
function for nuclear CAD (11). However, DHO could still
be readily diffuse from the nucleus into the mitochondria
as the latter are in close proximity to the nuclear membrane
(156).
Synthesis of the deoxyNTPs
DNA synthesis requires a source of the four dNTPs, which
derive from the ribonucleotides at the level of rNDPs by re-
duction at the 2′ position of the ribose subunit. The syn-
thesis of dNTPs occurs cytoplasmically using the enzyme
ribonucleotide reductase (RNR) (157), though the possibil-
ity of RNR activity inside mitochondria has been reported
(158). This enzyme acts upon the rNDP and reduces the
2′-OH of ribose to the deoxy state, using NADPH as the
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electron source via thioredoxin and thioredoxin reductase.
The resulting dNDPs are then converted to the dNTPs via
dinucleotide kinase and ATP.
The DNA-unique nucleotide, dNTP is synthesized by
methylation of dUMPby the action of thymidylate synthase
using N5,N10-methylene tetrahydrofolate as the methyl car-
bon donor. dUMP is itself formed by a specific phosphatase
activity on dUTP or by deamination of dCMP formed from
hydrolysis of DNA (99). The dTMP is then converted to
dTTP by the sequential action of two kinases.
The R1 subunit of RNR and TS are also regulated by
MYC (Table 1). RNR expression is cell cycle dependent
and as expected it rises during S phase (159,160). There is
an alternative form of the R2 protein called p53R2 that is
constitutively expressed at low levels but is upregulated in
TP53(+) cells in the presence of DNAdamage, and seems to
be involved inDNA repair (161–163). The supply of dNTPs
are moreover regulated at the substrate level by the supply
of NADPH and allosteric interactions of RNR with ATP,
dATP and the other dNTPs. RNR has two allosteric sites,
both on the RRM encoded subunit. One binds either ATP
(activating) or dATP (inhibitory). The ratio of the rATP to
dATP therefore regulates net flux to dNDP according to
demand––a high ratio of ATP/dATP favors a higher reduc-
tive flux andDNA synthesis, whereas a low ratio signals low
demand for dNDP. The other allosteric site regulates sub-
strate specificity (164). Thus binding of (d)ATP induces re-
duction of CDP or UDP, dGTP induces reduction of ADP
and dTTP induces reduction of GDP. Together, these ac-
tivities determine the supply of dNTPs during S phase (net
DNA synthesis) and for repair synthesis.
STABLE ISOTOPE TRACING OF NUCLEOTIDE SYN-
THESIS
Although the metabolic pathways for nucleotide
metabolism are well established, the detailed regula-
tion at the enzyme (such as substrate channeling) and
transcriptional levels under different conditions is less
well understood. In order to define such regulation and
the contribution of different nutrient sources for these
complex intersecting pathways, it is necessary to measure
the pathways in cells and tissues, using tracer technology
such that individual atoms can be traced from the source to
the product. In principle, radioisotopes can be used to trace
precursors through metabolic pathways into final products
(165,166). In practice stable (non-radioactive) isotopes
offer more versatility and have the advantage of being fully
compatible with live cells or tissues and making it possible
to follow the fate of individual atoms from a precursor
into detected products (167). The main analytical tools
are mass spectrometry and nuclear magnetic resonance
(NMR). Mass spectrometry distinguishes 13C or 15N from
the more abundant isotopes 12C and 14N by virtue of the
mass difference, which is nominally one mass unit. At
sufficiently high resolution, such as FT-MS, differences
in neutron mass can readily be detected. Thus the mass
of a nucleotide containing one 13C atom versus one 15N
atom differ by 0.00634 amu which is readily resolved at a
resolution of 400,000 (168). This means that simultaneous
dual labeling with both 15N and 13C can be used to deter-
mine the incorporation of the number and type of atoms
(isotopologues) into nucleotides. NMR in contrast depends
on the difference in magnetic properties of the nuclei of
13C versus 12C for example. 12C is magnetically silent,
whereas 13C can either be directly detected or indirectly by
its influence on the directly attached proton (92,169–170)
which has the advantage of greatly enhanced sensitivity.
NMR detects both the position (isotopomers) and the
amount of incorporation of the labeled atoms. The analysis
of the isotopomers and isotopologues of intermediates
and products provides very detailed information about the
biosynthetic routes to the products under study (25,167).
Thus use of 13C and/or 15N labeled precursors coupled
with labeled product analysis by MS and NMR offers the
optimal approach for this purpose, as these techniques can
directly detect the number and positions of 13C or 15N in
the intermediates and products of nucleotide biosynthesis,
thereby robustly defining the flow of atoms through the
intersecting pathways. Other stable isotopes can also be
used to measure nucleotide synthesis and incorporation
into RNA and DNA. Hellerstein’s group (14,171) has used
both 13C glucose and 2H glucose with GC-MS detection
of purine nucleotide released from DNA to follow DNA
synthesis in cells and tissues. The overall turnover of nucleic
acids in tissues can also be determined by measuring the
incorporation of deuterons from D2O into DNA (172).
Recently 14C-1 and 14C-6 glucose was used in comparison
with [1–2H]-glucose or [3–2H]-glucose with LC MS to
detect the transfer of a deuteron to NADP+ in the oxidative
branch of the PPP (166).
Our group has developed the stable isotope resolved
metabolomics or SIRM approach (173–175) for this
purpose, which has been applied to mapping nu-
cleotide biosynthesis in cultured cells or tissues in situ
(19,92,101,168,173,176–177). Figure 5 tracks the expected
incorporation of labeled atoms from 13C6-glucose ( , for
13C) and 13C5,15N2-glutamine ( for 13C and for 15N)
into nucleotide products via purine (PUR) and pyrimidine
(PYR) synthesis as well as feeder pathways including
glycolysis, the Krebs cycle in the absence or presence of
anaplerotic pyruvate carboxylation or glutaminolysis,
PPP and one-carbon pathway. Based on SIRM profiling
of the various labeled intermediates and products, these
intersecting pathways for nucleotide biosynthesis can be
rigorously reconstructed and quantified even in human
subjects in situ (154). Examples of stable isotope tracer
studies on nucleotide biosynthesis are described below.
Tracking ribose synthesis via the pentose phosphate pathway
The ribose unit of the nucleotides derives from the PPP, and
for most cells and tissues, this means that as few tissues are
gluconeogenic the carbon originates from glucose either ex-
ogenous or via G-1P by phosphorolysis of glycogen. Two-
dimensional (2D) NMR can be applied to crude cell or tis-
sue extracts and discriminates the ribose subunit of purine
and pyrimidine nucleotides as well as those of NAD+. The
TOCSY experiment detects the scalar interactions between
the ribose H1′–H2′–H3′–H4′ which appear as discrete cross
peaks.When the carbon atom is 12C, the cross peaks are sin-
gle, whereas if ◦C is present, it splits the attached proton res-
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onance into two peaks separated by the one-bond coupling
constant of 130–160Hz. The patterns of thee so-called satel-
lite peaks are characteristic according to which atoms are
enriched in 13C, which gives rise to the isotopomer distribu-
tion that can be quantified (167,178). Complementary iso-
tope edited experiments can be used to determine the com-
plete isotopomer distribution in complex systems as needed
(177,179). This is straightforward to demonstrate in the free
nucleotide pool in cells by 2D 1H NMR analysis, as shown
in Supplementary Figure S3. Here the ribose subunits of the
free nucleotide pools are highly enriched with 13C when the
cells are exposed to 13C glucose, but not at all when exposed
to 13C Gln. The production of 13C5-ribose-containing nu-
cleotides from 13C6-glucose, as determined by FT-ICR-MS
analysis (5 13C isotopologue in Supplementary Figure S4)
is also consistent with the PPP activity The use of glucose
as the primary carbon source for ribose biosynthesis applies
to many different cell types (92,168,175,179–180).
However, it is difficult to delineate whether the 13C5-
ribose labeling pattern results from oxidative, non-oxidative
or both branches of the PPP. The oxidative branch (Figure
1) generates ribose-5-phosphate from glucose-6-phosphate
(G6P) via decarboxylation of the C1 of G6P while produc-
ing two molecules of NADPH. This reaction is especially
important in cells that have a high demand for NADPH,
including erythrocytes (to remove H2O2 in a highly oxi-
dizing environment (181)) and proliferating cells that are
actively making fatty acids (166). The alternative non-
oxidative branch reversibly converts ribose-5-phosphate
and erythrose-4-phosphate into fructose-6-phosphate and
glyceraldehyde-3-phosphate, and vice versa (182), which
serves a dual purpose, namely to direct glucose carbon
back into glycolysis and for nucleotide ribose biosynthe-
sis. This branch does not generate NADPH. Boros et al.
have established a simple GC-MS based stable isotope
tracing method that can discriminate between these two
branches of pathways, while estimating the net lactic fer-
mentation flux (12,183–186). This method utilizes 13C2-
1,2 glucose as tracer, which undergoes decarboxylation to
become exclusively 13C-1-ribose via the oxidative branch
of the PPP, whereas via extensive scrambling in the non-
oxidative branch, ribose is labeled at the C1 and C2 posi-
tions. This scrambling arises from the reversibility of the
reactions catalyzed by transaldolase and transketolase (cf.
Figure 1A), which in fact may be exacerbated by the ex-
changes in the individual half reactions (187). Chemical ex-
change in reactions that are near equilibrium equilibrate la-
bel across the reaction, such that there can be label reach-
ing a metabolite even where there is net flux in the opposite
direction. This is a very general problem, that must be ac-
counted for in any atom-resolved tracer experiments. The
ratios of the different labeled ribose species provides an es-
timate of the relative flow through the oxidative and non-
oxidative pathways subject to the caveats noted by Kleijn
et al. (187). 14C-1,6 glucose has also been used to discrim-
inate between the oxidative and non-oxidative branches,
which relies on radiometric detection of CO2 released by
the oxidation at C1′ (166). NMRanalysis of free nucleotides
can determine positional enrichment in the ribose subunits
of intact nucleotides (92) without the need for fragmenta-
tion, which may provide a more direct discrimination of be-
tween the oxidative and non-oxidative branches and the rel-
ative flux through the two branches (188) (and A.N. Lane,
unpublished).
It appears that both pathways may operate leading to net
nucleotide ribose biosynthesis. Depending on the cell type,
and possibly the growth conditions, the oxidative branch
can account for very little to most of the flow of glucose
into ribose (12,101,182–183,185–186,189–192). Such direct
readout of the two pathway activities is required to de-
termine the functional consequences of relevant gene or
even enzyme expression in the two pathways (Table 1), as
post-translational and substrate level regulations can fur-
ther alter the metabolic outcome. Despite its complexity
and importance to cell proliferation and maintenance, the
flux through the PPP is only 1–7% of the net glucose flux to
pyruvate (183,188,193–194).
Tracking pyrimidine ring biosynthesis
The pyrimidine ring is synthesized independent of ribose-
5-P, with all but one reaction occurring in the cytoplasm.
The one exception is the DHODH reaction, which resides
on the mitochondrial membrane and is intimately coupled
to the electron transport chain (ETC). Mitochondria with
a defective ETC cannot make UMP. As Figures 2 and 5
show, four of the ring atoms of uracil derived from aspar-
tate, one from CO2 and the N3 from Gln via the cytoplas-
mic CPSII enzyme. Aspartate is a non-essential amino acid
present in blood plasma at about 20 M (195) and can be
transported into the cell by Na+-dependent anionic trans-
porters (196) or synthesized de novo by transamination of
oxalacetate (OAA) in either the mitochondria or the cyto-
plasm. This reaction in fact is an important component of
the malate/aspartate shuttle for transferring electrons from
NADH in the cytoplasm into mitochondria. In addition to
be the entry point of the Krebs cycle, OAA is the product of
the anaplerotic reaction catalyzed by pyruvate carboxylase
(PC), which is important in some cancers (179,197–198).
If aspartate and thus OAA is used for pyrimidine biosyn-
thesis, anaplerosis is needed to replenish OAA to sustain
the functioning of the Krebs cycle. In addition to PC,
another common anaplerotic reaction in cancer cells and
other proliferating cells (175,194) is glutaminolysis, inwhich
glutamine is first hydrolyzed to glutamate and ammonia
followed by either transamination with OAA to produce
Asp + -ketoglutarate (KG) (199) or oxidative deamina-
tion via GDH to KG + ammonium ions. KG can also
be converted to OAA by the normal functioning of the
Krebs cycle (86,125–127,200–204) (Figure 5). The relative
importance of these two anaplerotic reactions probably de-
pends on cell type and growth conditions to maintain en-
ergy production, nitrogen balance and anabolic metabolism
(175,179,194,198,205). The main difference between PC
and glutaminolytic anaplerotic pathways is the production
of ammonium ions by the latter, which in excess is toxic
to cells and must be dealt with. Moreover, glutaminolysis
competes with other Gln deamidation reactions as the di-
rect nitrogen source for many anabolic processes includ-
ing nucleotide synthesis (45,206–207). These considerations
would probably in part govern the choice of anaplerotic
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pathways that proliferating cells adopt to meet their growth
demand.
Again, tracer technologies can readily discriminate be-
tween glutamine and glucose as carbon sources and the
different feeder pathways leading to uracil ring biosynthe-
sis. [U-13C]-glucose enters the Krebs cycle via pyruvate ei-
ther as 13C2-acetyl CoA (via PDH) or 13C3-OAA (via PC),
which in turn gives rise to distinct labeling patterns in cit-
rate, Asp and ultimately the uracil ring. For example, PC-
( ) or PDH-derived 13C labeled Asp ( ) leads to the syn-
thesis of 13C3–4,5,6-UMP or 13C1–6-UMP, respectively, af-
ter one Krebs cycle turn, as shown in Figure 5. Although
[U-13C]-Gln also produces 13C3–4,5,6-UMP ( ) via the first
Krebs cycle turn, the 13C labeling patterns of Glu, KGand
citrate derived from [U-13C]-Gln are distinct from those de-
rived from [U-13C]-glucose (Figure 5) (25,81,92). Quantita-
tive analysis of the isotope distribution in these intermedi-
ates and products provides a means of determining the rel-
ative contribution of Gln and glucose to uracil biosynthesis
(92). It is generally found that in proliferating cells, whether
transformed or primary cells that are stimulated to prolifer-
ate, Gln is the preferred carbon source for pyrimidine ring
over glucose (92), but the precise balance is cell-dependent
(Lane & Fan, unpublished data), and possibly also condi-
tion dependent.
Cells in culture synthesize a large fraction of the aspar-
tate pool that is used for pyrimidine biosynthesis from glu-
tamine and glucose (81,92,101,179,208), even in media such
as RPMI that contain aspartate (0.15 mM) at concentra-
tions much higher than that present in blood (ca. 20 M).
Also, in cells treated with 13C5,15N2-Gln, it is found by
high resolution FT-ICR-MS that the aspartate pool is en-
riched mainly in the 13C415N and 13C414N isotopologues,
despite the presence of high levels of exogenous aspartate
(168). Both labeled Asp species are produced as a con-
sequence of glutaminolysis and transamination. 13C5,15N2
glutamine produces 13C5,15N1 glutamate and then 13C5-
KG via glutaminase and aminotransferase activity. KG
enters into the Krebs cycle to produce 13C4-OAA, which
is transaminated to form 13C415N1-Asp or 13C414N1-Asp
in the mitochondria (Figure 5). The aspartate-malate shut-
tle then transfers the labeled Asp to the cytoplasm to sup-
ply both carbon (C4–C6) and nitrogen (N1) for pyrimi-
dine biosynthesis. Thus, tracking the 13C and/or 15N fate
from labeled precursors to the various intermediates and
pyrimidine products enable a complete reconstruction of
the feeder and pyrimidine synthesis pathways, including the
delineation of different compartmental events.
However, there are few examples of this type of analy-
sis in the literature, further studies are needed to determine
whether other significant carbon sources are used by some
cells (e.g. threonine in stem cells (209)) or under different
growth conditions.
Tracking purine ring biosynthesis
The de novo synthesis of the purine ring is considerably
more complex than that of the pyrimidine ring, as the for-
mer is built up atom by atom on the phosphorylated ri-
bose unit in the cytoplasm (Figure 3). The carbon sources
are CO2, glycine and N10-formyltetrahydrofolate (Figure
4). Overall, glycine contributes up to four of the five car-
bon atoms in the purine ring, including indirectly via N10-
formyl THF. Glycine is a non-essential amino acid that is
present in human blood at ca. 0.25 mM (210) (HMDB:
url-http://www.hmdb.ca/). It can also be synthesized from
glucose via glycolytically produced 3-phosphoglycerate (3-
PGA) (Figure 4), via the choline-betaine pathway (211) or
from other sources such as threonine in some organisms,
though not humans (212). It appears that the glycine precur-
sor for purine biosynthesis is synthesized de novo from ser-
ine via glycolysis or mitochondrially via the glycine cleavage
system (213) (Figure 4), and there may even be a net efflux
of glycine in proliferating cells (214,215). In fact, exogenous
serine, or endogenously synthesized serine, but not exoge-
nous glycine is the major source of the one carbon units for
purine biosynthesis (216). The nitrogen in purines derives
from glycine (N7), glutamine (N3, N9) and Asp (N1) (Fig-
ure 3).
Incorporation of ring nitrogen atoms (N3 and N9) from
the amido nitrogen of glutamine is readily observed in the
free nucleotide pool using 15N-enriched Gln tracer coupled
with 2D 1H(15N}-HSQC NMR analysis. The N3 and N9
of AXP and GXP can be detected in crude cell or tissue ex-
tracts using the 2-bond scalar coupling of N9 to C8H or
N3 to C2H (cf. AXP data in Figure 6). This 15N incorpora-
tion pattern is evident in different cell types (19,92,177). In
addition, using high resolution FT-ICR-MS, the incorpora-
tion of 13C and 15N from [U-13C,15N]-Gln into nucleotide
can be simultaneously tracked by utilizing the difference in
the effective neutron mass in 15N versus 13C. This capability
makes it practical to reconstruct both carbon and nitrogen
pathways without the need for separate experiments (168).
Supplementary Figure S4 illustrates FT-ICR-MS analysis
of the 13C labeling pattern of AMP derived from [U-13C]-
glucose (168). Together with the NMR analysis for 13C la-
beled positions, we can ascertain that 13C5-AMP represents
AMP with fully 13C labeled ribose subunit, while 13C6-9-
AMP have fully 13C labeled ribose plus 1–4 13C labels in
the adenine ring (and see also (92,168,177). These data indi-
cate that PPP, glycolysis, Ser-Gly-N10-formyl THF variably
contribute to de novo synthesis of AMP. Thus, NMR and
MS are synergistic in defining the source and detailed label-
ing patterns for nucleotides, from which the feeder and nu-
cleotide synthesis pathways can be reconstructed and their
modulation by transcription factors or environmental con-
ditions can be elucidated.
Recently a tracer approach for following both NAD(P)H
production from deuteriated substrates was used to deter-
mine the synthesis of glycine in cancer cells and it was shown
that the serine/glycine pathway was a net producer of both
mitochondrial glycine and NADPH (213,217).
Salvage pathways
RNA in particular is constantly turned over in cells, both
during the production of mature RNAs from longer pre-
cursors and to regulate the amounts of, e.g. mRNA. The
breakdown of polymeric RNA and DNA results in release
of NMPs, which can be recycled by the action of the nu-
cleotide kinases. This process contributes to the nucleotide
pools but cannot be used for net synthesis. Cells may also
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Figure 6. 15N incorporation from [U-13C,15N]-glutamine into purines detected by HSQC. A549 cells were grown the presence of [U-13C,15N]-glutamine
for 24 h. 1H{15N} HSQC NMR spectra were recorded at 18.8 T using an INEPT delay optimized for two bond couplings in aromatic systems. The two
ring 15N atoms derived from the amido N of Gln (blue) are indirectly detected by their coupled protons (red) as cross-peaks of N3 to H2 and N9 to H8 in
the adenine ring of AXP. Reproduced with kind permission from Springer Science+Business Media from J. Biomolec NMR (Springer) J. Biomol NMR.
2011 April; 49(3–4): 267–280. doi:10.1007/s10858-011-9484-6 (figure 9).
transport nucleobases from the external environment and
add the appropriate sugar.
Addition of the nucleobase to ribose is achieved either via
the PRPP step for purines, or catalyzed by specific pyrimi-
dine phosphorylase to add the base to ribose-1-phosphate
(218). Cytidine and deoxycytidine can be salvaged by the
agency of cytidine deaminase, producing uridine or deoxy
uridine, and then feed into the uracil pathway (219). This
in essence randomizes the UTP/CTP pool and must be
accounted for where isotope labeling experiments are per-
formed. Cytidine can also be salvaged more directly via
uridine-cytidine kinase producing (d)CMP (220). The rel-
ative importance of salvage versus de novo synthesis likely
depend on the growth conditions and on the specific tissue.
Recently it has ben argued that salvage pathways are very
important in colorectal cancers for example, albeit without
the assistance of isotope tracers (221).
Tracking nucleotide incorporation into nucleic acids.
The free nucleotide pools in cells are straightforward
to measure as they are relatively abundant, and are
readily labeled using 13C glucose or 13C,15N glutamine
(92,168,177,179). It is also practical to extract both DNA
and RNA from 13C and/or 15N labeled cells and determine
incorporation of exogenously supplied labeled tracers into
nucleic acids (via free nucleotides) after hydrolysis to the
NMPs (183,185). Although not all of the free nucleotide
pool enters nucleic acids, it appears that there is a major
common pool of labeled free nucleotides that is used for
RNA synthesis (92).
Tracking nucleotide synthesis invivo
The amount of de novo nucleotide biosynthesis correlates
well with cell proliferation rates. On the other hand, tissues
typically have a low mitotic index, even in tumors (which
can be highly heterogeneous and may contain a rather low
fraction of cancer cells) (222), so that the amount of de
novo nucleotide biosynthesis is small. Nevertheless, using
[U-13C]-glucose tracing in SCID mice, 13C incorporation
into free nucleotide ribose was observed in some tissues
(176), as well as in lung tumors resected from human sub-
jects (175,223). The feeder pathways for nucleotide synthe-
sis haves also been traced in vivo in human glioblastomas
using [U-13C]-glucose as tracer (194,198). 13C2-glycine was
detected by 13C NMR in [U-13C]-glucose labeled glioblas-
toma tissues, demonstrating synthesis from glucose via the
3PGA-serine pathways (cf. Figure 4). This is despite the
presence of 0.25 mM glycine in blood (210). In addition to
the free nucleotide pool which is relatively well sampled by
good extraction procedures (92,168,224), it is also possible
to determine the enrichment inDNA andRNA (12,92,171–
172,183,225). With modern instrumentation, the mass iso-
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tope ratios are generally good, at around 1% accuracy for
medium resolution mass spectrometers, to <0.5% for high-
resolution FT-MS instruments. Isotope accuracy in NMR
is limited mainly by spectral quality rather than any instru-
mental issue, as the detectors are fundamentally linear over
a dynamic range of ca. 220. The major issues of accuracy
and precision are related to experimental design and sample
preparation. NMRmethods do not require any fragmenta-
tion of the nucleotides, whereas GC-MS does. The experi-
mental design must take into consideration multiple inputs
to the nucleotide synthesis (see above), as well as turnover
rates, which in tissues is complicated by the heterogeneity
of cells, the efficiency of extraction and the generation of
the nucleotides from the different kinds of polymeric mate-
rial. Nevertheless, with careful consideration of the kinet-
ics and of compartmentation, adequate models can be built
that account for the observations without an excess of pa-
rameters, as shown for example for the synthesis of UDP-
N-acetylglucosamine (173).
Thus, stable isotope tracers coupled with state-of-the-
science NMR and MS analysis for labeling patterns of rel-
evant metabolites provide an unprecedented opportunity
for tracking nucleotide biosynthesis in vivo, even in human
subjects, under different tissue contexts and pathological
conditions. These advances are expected to greatly accel-
erate our understanding in the regulation of human nu-
cleotide metabolism, the perturbation of which is crucial to
the pathogenesis of many human diseases, including cancer.
CONCLUSIONS AND FUTURE DIRECTIONS
Nucleotides are used in a wide variety of metabolic func-
tion sin all cells, as coenzymes, for regulation, for activat-
ing substrates, for anabolic purposes as well as providing
the subunits of the nucleic acids. Maintenance of nucleotide
levels is therefore fundamental to cellular function. Prolifer-
ating cells, whether normal division during embryogenesis
or in controlled proliferation in the hematopoietic system
and stem cell compartments for example, as well as dysreg-
ulated cell division in cancer all need to maintain the sup-
ply of nucleotides. Unsurprisingly then the supply of nu-
cleotides is strongly regulated and tied to the cell cycle. This
is achieved both at the gene expression level by a variety of
transcription factors as well as the substrates level regula-
tion of the large number of enzymes needed to synthesize
the nucleotides.
Although the basic nucleotide synthesis pathways are
known and their energy demand can be estimated, the spe-
cific requirement for nutrient precursors/energy and the
regulatory networks formodulating nucleotide biosynthesis
in dividing cells remain unclear, particularly in terms of de-
pendence on cell type and pathological conditions. This is in
part due to the lack of powerful tools for elucidating the ac-
tual paths from nutrient precursors through various feeder
pathways to de novo synthesized nucleotides. Furthermore,
the amount of RNA synthesis greatly exceeds the amount
of polymeric RNA present in a cell, owing to the extensive
turnover. Characterization of gene and protein expression
in these paths can provide useful clues, but such studies need
to be validated by functional pathway analysis.
Stable isotope tracers in conjunction with state-of-
the-science metabolomics methodologies is especially well
suited for such functional studies not only in model cells
and animals but also directly in human subjects. The rela-
tively few stable isotope tracer-based studies reported have
already uncovered important new insights into nucleotide
biosynthesis, such as preference for endogenously synthe-
sized precursors such as glycine and aspartate over those ex-
ternally supplied, and how resources are reallocated accord-
ing to the environmental conditions, especially in patho-
logical conditions such as cancers (‘metabolic reprogram-
ming’ (22,44)). Such information cannot be obtained with-
out tracer methods. These considerations point to the need
to be able to assess the nucleotide synthesis according to tis-
sue pathology and nature, for which these new technologies
can now be applied with some ease (176,194,197–198,226–
227). It is notable that many drugs are targeted at nucleotide
synthesis at the level of the availability of nucleotides or act
as chain terminators (32–39,228–229).
In the future we expect further systems biochemical ad-
vances in systems biochemical approaches in which the de-
tailed energy and anabolic pathways are integrated with the
‘feeder’ pathways and the specific gene expression networks
that are linked to the cell cycle and thus nucleotide demand
for DNA and RNA synthesis. As these are likely to be cell
type and environment specific, the modem high throughput
‘omics approaches, such as SIRM described in this review
are well suited to define the biochemical details of normal
and pathological cell function, which directly informs the
optimum modes for therapeutic intervention. As dysregu-
lations of nucleotide metabolism are commonly involved
in human disease pathogenesis, such understanding is ex-
pected to have important diagnostic and therapeutic ben-
efits in relevant human diseases including cancer and dia-
betes.
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